Variola Major (Smallpox) Completed Phase 2 Trials for Modified vaccinia ankara (DB15483)

Also known as: Small Pox / Smallpox / Smallpox (disorder) / Variola major (disorder) / Smallpox, unspecified

DBCOND0038255 (Variola Major (Smallpox))Completed2 IdentifierTitlePurposeDrugs
NCT00879762High Dose IMVAMUNE® in Vaccinia-Naive IndividualsPrevention
NCT00053482Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated AdultsPrevention
NCT00053495Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox VaccinationPrevention
NCT04957485Study to Assess the Safety and Pharmacokinetics of TPOXX® When Administered Orally for 28 DaysTreatment
NCT02038881Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV InfectionPrevention
NCT01668537A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy SubjectsPrevention
NCT00857493A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced SubjectsPrevention
NCT00686582An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 VaccineesPrevention
NCT00466245Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox VaccinePrevention
NCT00316524A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy SubjectsPrevention
NCT00189956Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.Prevention
NCT00050505Expanded Dryvax Dilution Study in Previously Vaccinated AdultsPrevention